. 2019 Jun 25;20(12):3111. doi: 10.3390/ijms20123111

Table 2.

Impact of subcutaneous estrogens treatment on platelet activation in mice. The arrows indicate the changes in platelet responses. 17β estradiol: E2. Progesterone: P4; medroxyprogesterone acetate: MPA.

	Molecule	Dose and Duration	Results
Rosenblum et al. [33]	E2	Pellet 0.5 mg, 12 days	Faster thrombosis (mesenteric arterioles)
Rosenblum et al. [34]	E2	Pellet 0.5 mg, 12 days	Faster thrombosis (cerebral microvessels)
Valera el al. [20]	E2	Pellet 200 μg/kg/day, 3 weeks	Protection against thromboembolism
Valera el al. [20]	E2	Pellet 200 μg/kg/day, 3 weeks	Aggregation and adhesion under flow ↘
Valera et al. [24]	E2 + P4	Pellet E2 80 μg/kg/day,	Protection against venous and arterial thrombosis
Valera et al. [24]	E2 + P4	P4 10 mg, 3 weeks	Protection against venous and arterial thrombosis
Freudenberger et al. [38]	E2 + MPA	MPA 27.7 µg/d E2: 1.1µg/d, 90 days	arterial thrombosis ↗
Geng et al. [35]	E2	1-μg 21-day slow-release pellet, 21 days	Aggregation ↘
Valera el al. [25]	Estetrol	Pellet 6 mg/kg/day, 3 weeks	Protection against thromboembolism
Valera el al. [25]	Estetrol	Pellet 6 mg/kg/day, 3 weeks	Adhesion under flow ↘